Caricamento...
ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics
Dolutegravir (DTG) is a potent integrase inhibitor of human immunodeficiency virus. Because DTG is a substrate of the efflux transporter ABCG2 and ABCG2 is highly polymorphic, we asked whether dose adjustment of DTG is needed for ABCG2-deficient individuals. Using Abcg2-null mice, the current work i...
Salvato in:
| Pubblicato in: | J Pharmacol Exp Ther |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
The American Society for Pharmacology and Experimental Therapeutics
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7292963/ https://ncbi.nlm.nih.gov/pubmed/32303561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.119.264424 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|